NKTR EBITDA | Nektar Therapeutics

Nektar Therapeutics (NKTR) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$42.34M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$39.05M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$31.67M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$36.23M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2010-03-31 to 2024-12-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$42.34M	(m)	$10.13M	(m)	$94.00K*	-$75.77M*	(m)	$39.13M	(m)	$2.00K
2026-03-31	Reported	(m)	-$39.05M	(m)	$10.86M	(m)	$18.00K	-$44.30M	(m)	$35.68M	(m)	$64.00K
2025-09-30	Reported	(m)	-$31.67M	(m)	$11.79M	(m)	$114.00K*	-$48.76M*	$0.00	$27.25M	(m)	-$33.00K
2025-06-30	Reported	(m)	-$36.23M	(m)	$11.18M	(m)	$37.00K*	-$45.74M*	$0.00	$29.89M	(m)	-$188.00K
2025-03-31	Reported	(m)	-$44.53M	(m)	$10.46M	(m)	$2.00K	-$49.05M	$0.00	$30.48M	(m)	$52.00K
2024-09-30	Reported	(m)	-$34.34M	(m)	$24.12M	(m)	$666.00K*	-$43.93M*	$4.43M	$35.03M	(m)	$9.00K
2024-06-30	Reported	(m)	-$49.77M	(m)	$23.49M	(m)	$186.00K*	-$37.70M*	$9.74M	$29.72M	(m)	$46.00K
2024-03-31	Reported	(m)	-$35.43M	(m)	$21.64M	(m)	$157.00K	-$47.89M	$8.53M	$27.41M	(m)	-$35.00K
2023-09-30	Reported	(m)	-$44.86M	(m)	$24.14M	(m)	$33.00K*	-$42.12M*	$12.43M	$24.07M	(m)	-$61.00K
2023-06-30	Reported	(m)	-$50.60M	(m)	$20.50M	(m)	$162.00K*	-$51.52M*	$6.99M	$29.68M	(m)	-$47.00K
2023-03-31	Reported	(m)	-$134.71M	(m)	$21.59M	(m)	$433.00K	-$51.91M	$7.06M	$30.47M	(m)	-$63.00K
2022-09-30	Reported	(m)	-$54.30M	(m)	$23.63M	(m)	$181.00K*	-$82.89M*	$4.97M	$33.59M	(m)	-$155.00K
2022-06-30	Reported	(m)	-$152.84M	(m)	$21.59M	(m)	$780.00K*	-$74.99M*	$5.12M	$42.74M	(m)	$100.00K
2022-03-31	Reported	(m)	-$116.56M	(m)	$24.82M	(m)	$4.20M	-$88.42M	$5.32M	$107.25M	(m)	$126.00K
2021-12-31	Reported	(m)	-$112.91M	(m)	$25.01M	(m)	(m)	(m)	$6.16M	$99.61M	(m)	(m)
2021-09-30	Reported	(m)	-$113.60M	(m)	$24.92M	(m)	$2.94M*	-$101.14M*	$5.31M	$103.74M	(m)	$112.00K
2021-06-30	Reported	(m)	-$110.20M	(m)	$28.33M	(m)	$3.28M*	-$82.90M*	$7.67M	$101.31M	(m)	$357.00K
2021-03-31	Reported	(m)	-$109.39M	(m)	$23.65M	(m)	$2.88M	-$77.08M	$5.76M	$95.60M	(m)	$92.00K
2020-12-31	Reported	(m)	-$110.72M	(m)	$23.46M	(m)	(m)	(m)	$4.32M	$102.72M	(m)	(m)
2020-09-30	Reported	(m)	-$103.05M	(m)	$30.03M	(m)	$1.91M*	-$52.67M*	$5.57M	$100.53M	(m)	$21.00K
2020-06-30	Reported	(m)	-$77.71M	(m)	$48.85M	(m)	$2.69M*	-$83.90M*	$5.77M	$96.44M	(m)	$144.00K
2020-03-31	Reported	(m)	-$133.63M	(m)	$50.57M	(m)	$900.00K	-$78.08M	$3.81M	$108.99M	(m)	$200.00K
2019-12-31	Reported	(m)	-$109.64M	(m)	$33.86M	(m)	(m)	(m)	$5.99M	$110.37M	(m)	(m)
2019-09-30	Reported	(m)	-$98.74M	(m)	$29.22M	(m)	$5.32M*	-$68.64M*	$4.93M	$99.05M	(m)	$99.00K
2019-06-30	Reported	(m)	-$110.97M	(m)	$23.32M	(m)	$11.64M*	-$53.92M*	$5.02M	$106.69M	(m)	$99.00K
2019-03-31	Reported	(m)	-$120.69M	(m)	$28.22M	(m)	$5.65M	-$80.89M	$5.44M	$118.46M	(m)	$137.00K
2018-12-31	Reported	(m)	-$100.30M	(m)	$39.83M	(m)	(m)	(m)	$7.46M	$108.88M	(m)	(m)
2018-09-30	Reported	(m)	-$98.63M	(m)	$27.76M	(m)	$1.82M*	-$71.41M*	$4.78M	$102.89M	(m)	-$900.00K
2018-06-30	Reported	(m)	$973.60M	(m)	$1.09B	(m)	$2.75M*	$959.64M*	$5.52M	$88.33M	(m)	$3.88M
2018-03-31	Reported	(m)	-$86.74M	(m)	$38.02M	(m)	$985.00K	-$52.47M	$6.65M	$99.42M	(m)	$265.00K
2017-12-31	Reported	(m)	-$24.03M	(m)	$95.47M	(m)	(m)	(m)	$9.75M	$81.43M	(m)	(m)
2017-09-30	Reported	(m)	$69.48M	(m)	$152.93M	(m)	$939.00K*	$93.08M*	$5.67M	$65.71M	(m)	$202.00K
2017-06-30	Reported	(m)	-$50.66M	(m)	$34.59M	(m)	$2.25M*	(m)	$8.99M	$60.26M	(m)	$99.00K
2017-03-31	Reported	(m)	-$54.44M	(m)	$24.73M	(m)	$4.09M	(m)	$6.13M	$61.06M	(m)	$133.00K
2016-12-31	Reported	(m)	-$32.15M	(m)	(m)	(m)	(m)	(m)	(m)	$50.23M	(m)	(m)
2016-09-30	Reported	(m)	-$32.90M	(m)	(m)	(m)	$507.00K*	(m)	(m)	$51.95M	(m)	$139.00K
2016-06-30	Reported	(m)	-$38.33M	(m)	(m)	(m)	$1.55M*	(m)	(m)	$52.35M	(m)	$127.00K
2016-03-31	Reported	(m)	-$9.48M	(m)	(m)	(m)	$1.68M	(m)	(m)	$49.27M	(m)	$167.00K
2015-12-31	Reported	(m)	-$29.36M	(m)	(m)	(m)	(m)	(m)	(m)	$47.13M	(m)	(m)
2015-09-30	Reported	(m)	$419.00K	(m)	(m)	(m)	$4.14M*	(m)	(m)	$43.23M	(m)	$92.00K
2015-06-30	Reported	(m)	-$43.47M	(m)	(m)	(m)	$3.52M*	(m)	(m)	$45.41M	(m)	$164.00K
2015-03-31	Reported	(m)	$43.04M	(m)	(m)	(m)	$1.06M	(m)	(m)	$47.01M	(m)	$213.00K
2014-12-31	Reported	(m)	-$37.49M	(m)	(m)	(m)	(m)	(m)	(m)	$38.49M	(m)	(m)
2014-09-30	Reported	(m)	$80.32M	(m)	(m)	(m)	$898.00K*	(m)	(m)	$34.20M	(m)	$248.00K
2014-06-30	Reported	(m)	-$22.92M	(m)	(m)	(m)	$668.00K*	(m)	(m)	$36.70M	(m)	$195.00K
2014-03-31	Reported	(m)	-$36.40M	(m)	(m)	(m)	$4.52M	(m)	(m)	$38.34M	(m)	$191.00K
2013-12-31	Reported	(m)	-$35.89M	(m)	(m)	(m)	(m)	(m)	(m)	$48.25M	(m)	(m)
2013-09-30	Reported	(m)	-$6.53M	(m)	(m)	(m)	$588.00K*	-$19.71M*	(m)	$43.91M	(m)	$193.00K
2013-06-30	Reported	(m)	-$32.60M	(m)	(m)	(m)	$478.00K*	-$34.34M*	(m)	$52.23M	(m)	$205.00K
2013-03-31	Reported	(m)	-$45.11M	(m)	(m)	(m)	$316.00K	-$38.11M	(m)	$45.62M	(m)	$212.00K
2012-12-31	Reported	(m)	-$43.38M	(m)	(m)	(m)	(m)	(m)	(m)	$46.37M	(m)	(m)
2012-09-30	Reported	(m)	-$32.90M	(m)	(m)	(m)	$2.57M*	-$27.17M*	(m)	$34.02M	(m)	$222.00K
2012-06-30	Reported	(m)	-$26.99M	(m)	(m)	(m)	$1.66M*	-$20.59M*	(m)	$33.20M	(m)	$93.00K
2012-03-31	Reported	(m)	-$37.93M	(m)	(m)	(m)	$1.52M	-$34.62M	(m)	$35.09M	(m)	$124.00K
2011-12-31	Reported	(m)	-$34.47M	(m)	(m)	(m)	(m)	(m)	(m)	$33.30M	(m)	(m)
2011-09-30	Reported	(m)	-$21.34M	(m)	(m)	(m)	$1.45M*	-$21.87M*	(m)	$31.02M	(m)	$92.00K
2011-06-30	Reported	(m)	-$34.26M	(m)	(m)	(m)	$3.08M*	-$34.79M*	(m)	$32.27M	(m)	$60.00K
2011-03-31	Reported	-$30.01M	(m)	(m)	(m)	-265.61%	$3.77M	-$14.87M	(m)	$30.18M	(m)	$148.00K
2010-12-31	Reported	(m)	-$20.54M	(m)	(m)	(m)	(m)	(m)	(m)	$31.45M	(m)	(m)
2010-09-30	Reported	(m)	-$6.22M	(m)	(m)	(m)	$13.36M*	-$22.16M*	(m)	$27.72M	(m)	$278.00K
2010-06-30	Reported	(m)	$1.87M	(m)	(m)	(m)	$4.82M*	-$19.95M*	(m)	$25.60M	(m)	$31.00K
2010-03-31	Reported	$791,000.00	(m)	(m)	(m)	2.38%	$3.97M	-$34.16M	(m)	$23.29M	(m)	$308.00K

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$140.10M	(m)	$55.23M	(m)	$171.00K	-$208.51M	$0.00	$117.33M	(m)	-$138.00K
2024-12-31	Reported	-$101.1M	(m)	(m)	(m)	-102.71%	$1.47M	-$175.71M	$30.69M	$120.91M	(m)	-$239.00K
2023-12-31	Reported	-$256.68M	(m)	(m)	(m)	-284.82%	$865.00K	-$192.61M	$33.77M	$114.16M	(m)	-$200.00K
2022-12-31	Reported	-$363.97M	(m)	(m)	(m)	-395.38%	$5.68M	-$304.01M	$21.64M	$218.32M	(m)	$3.21M
2022-09-30	Rolling	(m)	-$436.61M*	(m)	$95.04M*	(m)	(m)	(m)	$21.57M*	$283.20M*	(m)	(m)
2022-06-30	Rolling	(m)	-$495.90M*	(m)	$96.34M*	(m)	(m)	(m)	$21.90M*	$353.35M*	(m)	(m)
2022-03-31	Rolling	(m)	-$453.27M*	(m)	$103.08M*	(m)	(m)	(m)	$24.46M*	$411.92M*	(m)	(m)
2021-12-31	Reported	-$433.1M	(m)	(m)	(m)	-425.00%	$14.99M	-$412.66M	$24.90M	$400.27M	(m)	$557.00K
2021-12-31	Rolling	(m)	-$446.10M*	(m)	$101.91M*	(m)	(m)	(m)	$24.90M*	$400.27M*	(m)	(m)
2021-09-30	Rolling	(m)	-$443.91M*	(m)	$100.36M*	(m)	(m)	(m)	$23.06M*	$403.38M*	(m)	(m)
2021-06-30	Rolling	(m)	-$433.37M*	(m)	$105.47M*	(m)	(m)	(m)	$23.32M*	$400.17M*	(m)	(m)
2021-03-31	Rolling	(m)	-$400.87M*	(m)	$125.99M*	(m)	(m)	(m)	$21.42M*	$395.30M*	(m)	(m)
2020-12-31	Reported	-$412.61M	(m)	(m)	(m)	-269.83%	$7.26M	-$313.29M	$19.48M	$408.68M	(m)	$493.00K
2020-12-31	Rolling	(m)	-$425.11M*	(m)	$152.91M*	(m)	(m)	(m)	$19.48M*	$408.68M*	(m)	(m)
2020-09-30	Rolling	(m)	-$424.03M*	(m)	$163.31M*	(m)	(m)	(m)	$21.14M*	$416.32M*	(m)	(m)
2020-06-30	Rolling	(m)	-$419.72M*	(m)	$162.50M*	(m)	(m)	(m)	$20.50M*	$414.84M*	(m)	(m)
2020-03-31	Rolling	(m)	-$452.98M*	(m)	$136.97M*	(m)	(m)	(m)	$19.75M*	$425.09M*	(m)	(m)
2019-12-31	Reported	-$429.04M	(m)	(m)	(m)	-374.32%	$26.29M	-$328.68M	$21.37M	$434.57M	(m)	$613.00K
2019-12-31	Rolling	(m)	-$440.04M*	(m)	$114.62M*	(m)	(m)	(m)	$21.37M*	$434.57M*	(m)	(m)
2019-09-30	Rolling	(m)	-$430.69M*	(m)	$120.58M*	(m)	(m)	(m)	$22.85M*	$433.08M*	(m)	(m)
2019-06-30	Rolling	(m)	-$430.59M*	(m)	$119.13M*	(m)	(m)	(m)	$22.70M*	$436.93M*	(m)	(m)
2019-03-31	Rolling	(m)	$653.98M*	(m)	$1.18B*	(m)	(m)	(m)	$23.21M*	$418.57M*	(m)	(m)
2018-12-31	Reported	$696.73M	(m)	(m)	(m)	58.39%	$14.24M	$718.21M	$24.41M	$399.54M	(m)	$1.41M
2018-12-31	Rolling	(m)	$687.93M*	(m)	$1.19B*	(m)	(m)	(m)	$24.41M*	$399.54M*	(m)	(m)
2018-09-30	Rolling	(m)	$764.19M*	(m)	$1.25B*	(m)	(m)	(m)	$26.70M*	$372.08M*	(m)	(m)
2018-06-30	Rolling	(m)	$932.31M*	(m)	$1.37B*	(m)	(m)	(m)	$27.59M*	$334.90M*	(m)	(m)
2018-03-31	Rolling	(m)	-$91.94M*	(m)	$321.00M*	(m)	(m)	(m)	$31.06M*	$306.83M*	(m)	(m)
2017-12-31	Reported	-$47.04M	(m)	(m)	(m)	-15.29%	$9.68M	-$80.41M	$30.55M	$268.46M	(m)	$616.00K
2017-12-31	Rolling	(m)	-$59.64M*	(m)	$307.71M*	(m)	(m)	(m)	$30.55M*	$268.46M*	(m)	(m)
2017-09-30	Rolling	(m)	-$67.75M*	(m)	(m)	(m)	(m)	(m)	(m)	$237.26M*	(m)	(m)
2017-06-30	Rolling	(m)	-$170.14M*	(m)	(m)	(m)	(m)	(m)	(m)	$223.50M*	(m)	(m)
2017-03-31	Rolling	(m)	-$157.81M*	(m)	(m)	(m)	(m)	(m)	(m)	$215.59M*	(m)	(m)
2016-12-31	Reported	-$99.66M	(m)	(m)	(m)	-60.24%	$6.39M	-$117.02M	$30.21M	$203.80M	(m)	$876.00K
2016-12-31	Rolling	(m)	-$112.86M*	(m)	(m)	(m)	(m)	(m)	(m)	$203.80M*	(m)	(m)
2016-09-30	Rolling	(m)	-$110.07M*	(m)	(m)	(m)	(m)	(m)	(m)	$200.70M*	(m)	(m)
2016-06-30	Rolling	(m)	-$76.75M*	(m)	(m)	(m)	(m)	(m)	(m)	$191.98M*	(m)	(m)
2016-03-31	Rolling	(m)	-$81.90M*	(m)	(m)	(m)	(m)	(m)	(m)	$185.04M*	(m)	(m)
2015-12-31	Reported	-$17.97M	(m)	(m)	(m)	-7.79%	$11.20M	(m)	(m)	$182.79M	(m)	$506.00K
2015-12-31	Rolling	(m)	-$29.37M*	(m)	(m)	(m)	(m)	(m)	(m)	$182.79M*	(m)	(m)
2015-09-30	Rolling	(m)	-$37.49M*	(m)	(m)	(m)	(m)	(m)	(m)	$174.15M*	(m)	(m)
2015-06-30	Rolling	(m)	$42.41M*	(m)	(m)	(m)	(m)	(m)	(m)	$165.12M*	(m)	(m)
2015-03-31	Rolling	(m)	$62.96M*	(m)	(m)	(m)	(m)	(m)	(m)	$156.41M*	(m)	(m)
2014-12-31	Reported	(m)	-$16.48M	(m)	(m)	(m)	$9.98M	(m)	(m)	$147.73M	(m)	-$512.00K
2014-12-31	Rolling	(m)	-$16.48M*	(m)	(m)	(m)	(m)	(m)	(m)	$147.73M*	(m)	(m)
2014-09-30	Rolling	(m)	-$14.89M*	(m)	(m)	(m)	(m)	(m)	(m)	$157.49M*	(m)	(m)
2014-06-30	Rolling	(m)	-$101.74M*	(m)	(m)	(m)	(m)	(m)	(m)	$167.20M*	(m)	(m)
2014-03-31	Rolling	(m)	-$111.43M*	(m)	(m)	(m)	(m)	(m)	(m)	$182.73M*	(m)	(m)
2013-12-31	Reported	(m)	-$120.13M	(m)	(m)	(m)	$4.09M	-$38.53M	(m)	$190.01M	(m)	$2.25M
2013-12-31	Rolling	(m)	-$120.13M*	(m)	(m)	(m)	(m)	(m)	(m)	$190.01M*	(m)	(m)
2013-09-30	Rolling	(m)	-$127.62M*	(m)	(m)	(m)	(m)	(m)	(m)	$188.13M*	(m)	(m)
2013-06-30	Rolling	(m)	-$153.99M*	(m)	(m)	(m)	(m)	(m)	(m)	$178.24M*	(m)	(m)
2013-03-31	Rolling	(m)	-$148.38M*	(m)	(m)	(m)	(m)	(m)	(m)	$159.21M*	(m)	(m)
2012-12-31	Reported	(m)	-$141.20M	(m)	(m)	(m)	$10.58M	-$129.76M	(m)	$148.68M	(m)	$406.00K
2012-12-31	Rolling	(m)	-$141.20M*	(m)	(m)	(m)	(m)	(m)	(m)	$148.68M*	(m)	(m)
2012-09-30	Rolling	(m)	-$132.29M*	(m)	(m)	(m)	(m)	(m)	(m)	$135.60M*	(m)	(m)
2012-06-30	Rolling	(m)	-$120.73M*	(m)	(m)	(m)	(m)	(m)	(m)	$132.61M*	(m)	(m)
2012-03-31	Rolling	(m)	-$128.00M*	(m)	(m)	(m)	(m)	(m)	(m)	$131.68M*	(m)	(m)
2011-12-31	Reported	(m)	-$123.94M	(m)	(m)	(m)	$9.72M	-$113.74M	(m)	$126.77M	(m)	$1.02M
2011-12-31	Rolling	(m)	-$123.94M*	(m)	(m)	(m)	(m)	(m)	(m)	$126.77M*	(m)	(m)
2011-09-30	Rolling	(m)	-$110.01M*	(m)	(m)	(m)	(m)	(m)	(m)	$124.92M*	(m)	(m)
2011-06-30	Rolling	(m)	-$94.89M*	(m)	(m)	(m)	(m)	(m)	(m)	$121.63M*	(m)	(m)
2011-03-31	Rolling	(m)	-$58.76M*	(m)	(m)	(m)	(m)	(m)	(m)	$114.95M*	(m)	(m)
2010-12-31	Reported	(m)	-$28.25M	(m)	(m)	(m)	$31.46M	-$55.87M	(m)	$108.06M	(m)	$881.00K
2010-12-31	Rolling	(m)	-$28.25M*	(m)	(m)	(m)	(m)	(m)	(m)	$108.06M*	(m)	(m)
2009-12-31	Reported	(m)	-$95.13M	(m)	(m)	(m)	$16.39M	$39.74M	(m)	$95.11M	(m)	-$253.00K

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
UroGen Pharma Ltd. (URGN)		$2.015B	-18.42
PERRIGO Co plc (PRGO)	Ireland	$2.038B	-0.79
Nuvation Bio Inc. (NUVB)	United States	$2.007B	-13.12
Generate Biomedicines, Inc. (GENB)	United States	$2.052B
Biohaven Ltd. (BHVN)	United States	$1.990B	-3.83
AGIOS PHARMACEUTICALS, INC. (AGIO)	United States	$1.962B	-5.38
Trevi Therapeutics, Inc. (TRVI)	United States	$2.091B	-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)	United States	$2.105B	-35.55
Braveheart Bio, Inc. (BRVE)	United States	$2.106B
Sarepta Therapeutics, Inc. (SRPT)	United States	$1.941B	-13.89